SCDT-13. PHASE I CLINICAL TRIAL ON SYSTEMIC PD-1 BLOCKADE IN COMBINATION WITH DIRECT INTRA-TUMORAL INJECTION OF CTLA-4/PD-1 IMMUNE CHECKPOINT INHIBITION FOLLOWING RESECTION OF RECURRENT GLIOBLASTOMA

Recurrent glioblastoma is a devastating disease for which no treatment has demonstrated to improve overall survival in a randomized clinical trial. Anti-tumor Cytolytic T-cell (CTL) activity is suppressed by the CTLA4 and PD-1 immune-checkpoint receptors. Nivolumab(NIVO) is an IgG-4 mAb that blocks...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Duerinck, Johnny, Four, Stephanie Du, Salama, Lailia Ben, De Cremer, Jennifer, Van Binst, Anne, Everaert, Hendrik, Theuns, Pieter, Rogiers, Anne, Neyns, Bart
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692518/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.1096
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados